Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Investor Presentation (February 2018)
28 slides from Dr. Reddy's Laboratories's investor presentation, February 2018
Slide 1: Investor Presentation
Investor Presentation February 2018 Dr. Reddy’s Laboratories Limited Hyderabad, India BSE: 500124 | NSE: DRREDDY | NYSE: RDY
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Contents
Contents Our Purpose Company Overview Recent Business Highlights Growth Roadmap Optimistic Future 3
Slide 4: Our Purpose
Our Purpose We accelerate access to affordable and innovative medicines Because Good Health Can’t Wait.
Slide 5: Our Purpose Guides Our Customer Value Proposition Leading to Specific Strategic Choices
Our Purpose Guides Our Customer Value Proposition Leading to Specific Strategic Choices PURPOSE OUR PROMISES Bringing expensive medicine within reach We accelerate access to affordable medicines Addressing unmet patient needs because Helping patients manage disease better Good Health Enabling and he
Slide 6: Company Overview
COMPANY OVERVIEW e @
Slide 7: Multidimensional business model to sustain long-term growth
Multidimensional business model to sustain long-term growth UNBRANDED BRANDED PROPRIETARY (US + EU) (EM + INDIA) PRODUCTS • Continued growth for mega Current • Maximize the base business • Monetize the complex/ limited brands through patient centric initiatives revenues through volume competition as
Slide 8: Key strengths and capabilities
Key strengths and capabilities Collaboration across business units Industry Vertically leading Early mover integrated Deep market product advantage organization with presence development in Biosimilars modern skills infrastructure Several niche product Branded generic First to launch Biosimila
Slide 9: Formulation manufacturing infrastructure and capabilities
Formulation manufacturing infrastructure and capabilities DOSAGE FORM CAPABILITIES DETAILS 10 Facilities out of which Tablets, Capsules, Pellets, Oral Solids bi-layers, Modified / • 4 US FDA approved of which 2 are located in USA (22 bn pills annual) Extended release, ODTs • 3 MHRA approved 3 Facili
Slide 10: Globalized R&D to Access the Right Talent to Solve Complex Scientific Challenges
Globalized R&D to Access the Right Talent to Solve Complex Scientific Challenges Complex Complex Injectable Chemistry Centre Centre of of Excellence Excellence Cambridge, UK Leiden, Netherlands Canada Germany UK USA Italy Product Development Complex Centres Generics & Hyderabad & Bangalore Proprieta
Slide 11: Recent Business Highlights
Recent Business Highlights 11
Slide 12: Delivering affordable generic alternatives in Unbranded Markets
Delivering affordable generic alternatives in Unbranded Markets 12 NEW PRODUCTS LAUNCHED IN NORTH AMERICA SO FAR THIS FISCAL Sevelamer Carbonate Tablets launched in the U.S. Market • Affordable alternative for complex, limited-competition product • Fourth limited-competition launch this fiscal year
Slide 13: Biosimilars and small molecule Oncology assets fueling global expansion
Biosimilars and small molecule Oncology assets fueling global expansion Successful launches of Oncology products in EM and EU • Colombia, Brazil, Algeria, Spain, Italy Reditux™ paving the way for the entry of upcoming Biosimilar assets in new markets • Currently approved in 17 countries and availabl
Slide 14: Making a difference through Patient-centric Initiatives in Emerging Markets
Making a difference through Patient-centric Initiatives in Emerging Markets Our first wave of patient-centric packaging has been received well Four India Star awards for patient-centric packaging Push Tab feature in carton to (selected from 622 entries); now qualify for Asia star and Integrated fl
Slide 15: Addressing unmet needs in Derma and Neurology
Addressing unmet needs in Derma and Neurology Commercial Updates First set of launches Zembrace™ and Sernivo™ ramping up well, continue to focus on accelerating the commercial business’ path to profitability Promius Pharma recognized as an emerging R&D driven commercial organization in the neuro
Slide 16: Our Quality Journey
Our Quality Journey WE ARE COMMITTED TO EXCELLENCE IN QUALITY AND TO BEING THE BEST IN THE INDUSTRY U.S. FDA Audit Updates Sites Previously on Warning Letter CTO 5: Three observations in audit - Received EIR CTO 6: Two Observations in audit – EIR Awaited FTO 7 Sterile Plant: Received EIR: compliance
Slide 17: Growth Roadmap
Growth Roadmap e « ) @
Slide 18: Well-positioned for long-term profitable growth
Well-positioned for long-term profitable growth Current FY18 - 21 FY22-25 NAG: NAG: Strong and proven track Complex Injectables, Patches/ Topicals 505 b2 Generics, C2s, record in base businesses OTC Brands Non-substitutable Generics India: India: Deliberate efforts in Ramp-up Biosimila
Slide 19: North America Generics: Growth driven by limited competition products
North America Generics: Growth driven by limited competition products 2017 2021 • More than 50% of revenues to come from • Oral solid dosages account for almost 80% of Injectables, Topicals and other complex Portfolio the current revenues dosage forms • Injectables accounting for 20% of the revenues
Slide 20: India & Emerging Markets: Growth driven by patient centric initiatives
India & Emerging Markets : Growth driven by patient centric initiatives 2017 2021 • Portfolio augmentation and productivity improvement • Focus on mega brands • Step-up in Chronic and Super-specialty therapies expansion • India Strategic business development and M&A efforts • Improvement in new • Di
Slide 21: Biologics: Maximizing value of current assets in near to mid-term
Biologics: Maximizing value of current assets in near to mid-term while pursuing global development EU/US approval enabling studies initiated for pegfilgrastim Rituximab and bevacizumab approval enabling studies for EU/US expected to be BIOLOGICS REVENUE HAS GROWN AT APPROX. initiated in next 4 - 6
Slide 22: Biologics: Creating substantial value in long term from new portfolio choices
Biologics: Creating substantial value in long term from new portfolio choices while driving R&D productivity 6 commercial products; > 50 filings across 14 major countries FY20 Product Portfolio 5 new products in clinical development Emerging Markets Revenue: ~ $150Mn FY20 Business Profile Developed
Slide 23: Proprietary Products: Aspiring to build a $400 million business by FY22
Proprietary Products: Aspiring to build a $400 million business by FY22 through a low-risk innovation model Specialty Dermatology Franchise • Established with the goal to address unmet needs of specific patient segments in • 3 Products approved; 1 asset commercialized Dermatology & Neurology and 2 l
Slide 24: Optimistic Future
OPTIMISTIC FUTURE e « ) -)
Slide 25: To Summarize:
To Summarize: Top Line Growth with Healthy Profitability Well-positioned 1 Core business performance remains Strong for sustained profitable growth given our strong base business & proven 2 Growth levers are proven, vigorously executed and Continue to Deliver capability in complex generics with stra
Slide 26: 2018 Key Priorities
2018 Key Priorities Strengthening Manufacturing & Quality Create culture encouraging Transparency and Compliance Creating Leaner and Flexible cost structures Focus on Manufacturing and R & D Network Rationalization, Improving Plant Operating Efficiency, R&D Productivity and Portfolio Optimizatio
Slide 27: Good Health Can't Wait.
Good Health Can’t Wait.
Slide 28: Contacts
Contacts Investor relations Media relations Saunak Savla Calvin Printer [email protected] [email protected] (Ph: +91-40-49002135) (Ph: +91-40-49002121) About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committ
Dr. Reddy's Laboratories — Investor Presentation (February 2018) on 6ix